No Data
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Maintains Target Price $5
Minerva Neurosciences: Hold Rating Amid Regulatory Challenges and Uncertain Drug Development
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges
Minerva Neurosciences GAAP EPS of $2.97
Minerva Neurosciences: Interactions With FDA Continue With Goal of Addressing Questions Raised in Roluperidone CRL >NERV
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
No Data
No Data